Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden

Joanne D Stockton; Louise Tee; Celina Whalley; Jonathan James; Mark Dilworth; Rachel Wheat; Thomas Nieto; Ian Geh; Andrew D Beggs

doi:10.1101/2020.02.01.20019794

Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden

Joanne D Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Andrew D Beggs

Research output: Working paper/Preprint › Preprint

Original language	English
Publisher	medRxiv
DOIs	https://doi.org/10.1101/2020.02.01.20019794
Publication status	Published - 4 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1101/2020.02.01.20019794

Cite this

@techreport{a0a723bee53e40ba83df325940a737b9,

title = "Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden",

author = "Stockton, {Joanne D} and Louise Tee and Celina Whalley and Jonathan James and Mark Dilworth and Rachel Wheat and Thomas Nieto and Ian Geh and Beggs, {Andrew D}",

year = "2020",

month = feb,

day = "4",

doi = "10.1101/2020.02.01.20019794",

language = "English",

publisher = "medRxiv",

type = "WorkingPaper",

institution = "medRxiv",

}

TY - UNPB

T1 - Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden

AU - Stockton, Joanne D

AU - Tee, Louise

AU - Whalley, Celina

AU - James, Jonathan

AU - Dilworth, Mark

AU - Wheat, Rachel

AU - Nieto, Thomas

AU - Geh, Ian

AU - Beggs, Andrew D

PY - 2020/2/4

Y1 - 2020/2/4

UR - https://doi.org/10.1101/2020.02.01.20019794

U2 - 10.1101/2020.02.01.20019794

DO - 10.1101/2020.02.01.20019794

M3 - Preprint

BT - Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden

PB - medRxiv

ER -